Adherium Highlights Milestones Achieved in Advance of 2018

/in

21 Dec 2017

San Mateo, CA – December 20, 2017: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today highlighted milestones achieved in advance of 2018.

“As we conclude December and the calendar year, we are accelerating realization of our vision of stronger partnerships between patients and physicians, facilitated by easier adherence to the well-designed personal management plans that represent the last mile in healthcare,” said Arik Anderson, CEO of Adherium. “The tragedy of asthma and COPD – where we are focused today – is despite the advances made in therapies, and by physicians’ who’ve achieved a better understanding of respiratory disease, we are still being held back from sufficiently realizing those gains in patients’ lives.”

Asthma continues to be the third-ranking cause of hospitalization for children under 15 years of age in the U.S[i]. It is the leading cause of missed school days among children 5 to 17[ii]. Families continue to struggle to cope with asthma, as every missed day of school means missed work. Students with asthma may be at a higher risk of poor performance[iii].

“Technology that combines the most clinically-proven precision monitoring with the focused translation of a physician’s guidance into day-to-day care management can bridge the gap that exists today between medical science and the lives we live,” said Anderson.

To achieve this, Adherium accomplished a number of key milestones ahead of 2018, which leaves the company poised to deliver on its promise in the New Year –

  • Granted FDA clearance of the SmartTouch™ sensor for AstraZeneca’s Symbicort®
  • Developed next-generation mobile apps and a cloud software platform
  • Developed and shipped an enhanced version of the SmartTurbo™ device with additional sensors, allowing more refined management of asthma and COPD
  • Supported AstraZeneca’s ongoing rollout of the SmartTurbo™ device in Europe and an Australian commercial rollout, including to 130 respiratory clinicians
  • Reached over 100,000 devices distributed
  • Strengthened Adherium’s IP portfolio in the U.S.

“By the end of our second fiscal quarter, we will have shipped more than 12,500 devices, and I am confident we will achieve or surpass the fiscal year goal of 25,000 devices for the year,” said Anderson.

Adherium’s relationship with AstraZeneca has evolved from development to commercialization and Adherium is progressing toward launching the SmartTouchTM device for use with Symbicort in the U.S., following successful distribution in Europe and Australia. A disciplined program is underway to highlight unmet demand in the U.S. via a direct to consumer campaign, expand opportunities with providers and payers to respond to pressure from value-based care requirements, and meet health plan member demands in a volatile and fast-evolving payer market.

 

[i] Asthma’s Impact on Children and Adolescents. Atlanta: National Center for Environmental Health, Centers for Disease Control and Prevention. (No authors given.) 8 June 2005.

[ii] Asthma Facts and Figures . Washington: Allergy and Asthma Foundation of America.

[iii] Taras H, Potts-Datema W. “Childhood Asthma and Student Performance at School.” Journal of School Health, 75(8): 296-312, 2005.